Biotech Alexion has issued a press release announcing that FDA has approved, two months earlier than scheduled, its ALXN1210 therapy for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare condition. The drug will be marketed as Ultomiris, the company has added.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,